All In Biotech

Drug Trial Radar · NCT00323856

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Phase IV A Study of Immunologic Safety for Alphanate in Previously Treated Patients Diagnosed With Severe Hemophilia A

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

51

Actual

Start

Apr 8, 2003

Primary completion

Dec 11, 2018

Study completion Dec 14, 2018

Sponsor

Lead sponsor
Grifols Biologicals, LLCIndustry
Sponsor type
Industry
First posted
May 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the immunologic and overall safety associated with long-term use of Alphanate in subjects diagnosed with severe hemophilia A (Factor VIII:C less than 0.01 IU/ml), who have been previously treated with plasma-derived Factor VIII products other than Alphanate and who have no history of developing either antibody inhibitors to Factor VIII or nonspecific inhibitors of coagulation.

Conditions

  • Severe Hemophilia A

Interventions

  • Alphanate SD/HTDrug

    Plasma-derived preparation of Factor VIII

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Factor VIII (FVIII) Inhibitor DevelopmentTime frame: Up to Month 30

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Katedra i Klinika Hematologii Collegium Medicum UJ

    Krakow, Poland

  • Oddzial Chorob Wewnetrznych i Hematologii

    Poznan, Szkolna, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.